subject: Pwrm And Skymark Research Colaborates In The Medical Industry! Brought To You By Pennytobuck.com [print this page] Vermillion, IncVermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and women?s health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the ?OVA1 Test?), which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet; Copenhagen University Hospital; The Ohio State University Research Foundation; Stanford University; and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize up to three diagnostic tests.
Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics company, today announced that The NASDAQ Stock Market LLC has approved its application for the relisting of its common stock on The NASDAQ Global Market. The Company's shares will begin trading on The NASDAQ Global Market when the market opens on Tuesday, July 6, 2010 under the symbol "VRML."
"We are extremely pleased to resume trading on NASDAQ. In the first six months of the year, VRML has accomplished a number of significant tasks that very few companies successfully attain -- beginning with the Company's receipt of confirmation of its Plan of Reorganization in January and culminating today with the Company's relisting on NASDAQ," said Gail S. Page, CEO and Chairperson of the Board of Directors of VRML. "These accomplishments reflect the financial and operational progress we have achieved in recent quarters and speak directly to the fundamental strengths of VRML core business."
Skymark Research, a leading provider of small- and micro-cap independent investment research initiated coverage on Power3 Medical Products, Inc. (OTCBB:PWRM).
Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php.
